Growth hormone peptides produce results that persist somewhat after stopping (particularly body composition improvements), but levels do decline
GLP-1 receptor agonists like semaglutide have shifted weight management from a willpower-only model to a medically supervised treatment plan
It was no less surprising, therefore, that most had mutations in BRAF or RAF1,67 a perfectly understandable finding today, since we know that these melanomas belong to pathway I (low-CSD) and that mutations in BAP1 are yet another event in transformation to melanoma
328 Over recent years, studies have found that GIP treatment in humans reduces bone resorption, with one study also finding that this hormone additionally increases the rate of bone formation
medRxiv (2023) 2004:23288404
doi:10.1097/01.jcp.0000125688.05091.8f